Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Introduction: Standardization of mesenchymal stromal cells (MSCs) manufacturing is urgently needed to enable translational activities and ultimately facilitate comparison of clinical trial results. In this work we describe the adaptation of a proprietary method for isolation of a specific umbilical cord tissue-derived population of MSCs, herein designated by its registered trademark as UCX®, towards the production of an advanced therapy medicinal product (ATMP). Methods: The adaptation focused on different stages of production, from cell isolation steps to cell culturing and cryopreservation. The origin and quality of materials and reagents were considered and steps for avoiding microbiological and endotoxin contamination of the final cell product were implemented. Cell isolation efficiency, MSCs surface markers and genetic profiles, originating from the use of different medium supplements, were compared. The ATMP-compliant UCX® product was also cryopreserved avoiding the use of dimethyl sulfoxide, an added benefit for the use of these cells as an ATMP. Cells were analyzed for expansion capacity and longevity. The final cell product was further characterized by flow cytometry, differentiation potential, and tested for contaminants at various passages. Finally, genetic stability and immune properties were also analyzed. Results: The isolation efficiency of UCX® was not affected by the introduction of clinical grade enzymes. Furthermore, isolation efficiencies and phenotype analyses revealed advantages in the use of human serum in cell culture as opposed to human platelet lysate. Initial decontamination of the tissue followed by the use of mycoplasma- and endotoxin-free materials and reagents in cell isolation and subsequent culture, enabled the removal of antibiotics during cell expansion. UCX®-ATMP maintained a significant expansion potential of 2.5 population doublings per week up to passage 15 (P15). They were also efficiently cryopreserved in a DMSO-free cryoprotectant medium with approximately 100% recovery and 98% viability post-thaw. Additionally, UCX®-ATMP were genetically stable upon expansion (up to P15) and maintained their immunomodulatory properties. Conclusions: We have successfully adapted a method to consistently isolate, expand and cryopreserve a well-characterized population of human umbilical cord tissue-derived MSCs (UCX®), in order to obtain a cell product that is compliant with cell therapy. Here, we present quality and safety data that support the use of the UCX® as an ATMP, according to existing international guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications
Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt2 · Cited by 507 · cited 1×
“The hPL-specific down-regulation of certain genes, such as CCL5, FGF2 and PTGES (which regulates the expression of PGE2), could partially compromise the potential therapeutic effects attributed to MSCs through paracrine recruitment of resident MSCs, angiogenesis and immunosuppression, respectively [13-17].”
Background
Cited by
Miranda, J. P., Camões, S. P., Gaspar, M. M., Rodrigues, J. S., Carvalheiro, M., Bárcia, R. N., Cruz, P., Cruz, H., Simões, S., & Santos, J. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00018 · Cited by 109
Self-citationCamões, S. P., Bulut, O., Yazar, V., Gaspar, M. M., Simões, S., Ferreira, R., Vitorino, R., Santos, J. M., Gursel, I., & Miranda, J. P. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.01.013 · Cited by 55
Self-citationBárcia, R. N., Santos, J. M., Teixeira, M., Filipe, M., Pereira, A. R. S., Ministro, A., Água-Doce, A., Carvalheiro, M., Gaspar, M. M., Miranda, J. P., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.11.008 · Cited by 40
Self-citationMiranda, J. P., Filipe, E., Fernandes, A. S., Almeida, J. M., Martins, J. P., De La Fuente, A., Abal, M., Barcia, R. N., Cruz, P., Cruz, H., et al. (2015) · Cell Transplantation · doi:10.3727/096368913x676231 · Cited by 38
Self-citationProduction and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use
Bieback, K., Kuçi, S., & Schäfer, R. (2019) · Transfusion · doi:10.1111/trf.15252 · Cited by 24
“Martins et al.(60) analyzed 20 metaphases without indications of aberrations and did not observe teratoma formation after in vivo administration.”
Background
Metadata
- Authors
- Martins, J. P., Santos, J. M., Almeida, J. M., Filipe, M. A., de Almeida, M. V. T., Almeida, S. C. P., Água-Doce, A., Varela, A., Gilljam, M., Stellan, B., Pohl, S., Dittmar, K., Lindenmaier, W., Alici, E., Graça, L., Cruz, P. E., Cruz, H. J., & Bárcia, R. N.
- Venue
- Stem Cell Research & Therapy
- Published
- 2014-01-17
- Volume
- 5
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2127526938
- Cited by
- 65
- References
- 3
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.